Business
TelyRx Announces First Quarter 2026 Financial Results
Clearwater, Florida--(Newsfile Corp. - May 12, 2026) - TelyRx Holdings Inc. (TSX: TELY) (" Tely...
About this update from Telyrx Holdings Inc.
[{"type":"text","content":"TelyRx Announces First Quarter 2026 Financial ResultsClearwater, Florida--(Newsfile Corp. - May 12, 2026) - TelyRx Holdings Inc. (TSX: TELY) (\"TelyRx\" or the \"Company\"), a vertically integrated, technology-enabled healthcare and pharmacy services company, today announced financial results for the first quarter ended March 31, 2026. All dollar amounts are expressed in U.S. dollars.Highlights for the First Quarter of 2026Revenue increased to $19.4 million, compared to $14.3 million in Q4 2025 and $6.9 million in Q1 2025Number of Prescriptions Filled increased to 236,000 compared to 177,000 in the fourth quarter of 2025 and 82,000 in the first quarter of 2025Net Loss increased to $4.7 million, compared to a loss of $3.1 million in Q4 2025 and nil in Q1 2025Adjusted EBITDA1loss increased to $2.3 million, compared to a loss of $2.1 million in Q4 2025 and a positive $0.2 million in Q1 2025Completion of Go-Public Transaction - On March 31, 2026, TelyRx, Inc. completed its reverse takeover transaction of Apolo V Acquisition Corp., now TelyRx, and the Company's subordinate voting shares commenced trading on the TSX under the symbol \"TELY\" on April 7, 2026\"Our first quarter 2026 results reflect the growing demand for convenient, affordable healthcare,\" said Vanessa Slowey, President and Chief Executive Officer of TelyRx. \"Our 35% sequential revenue growth over the prior quarter, 69,000 new customers acquired all while maintaining a majority of revenue coming from repeat customers demonstrates that we are not just acquiring patients, we are earning their long-term loyalty. We have built a vertically integrated platform to capture one of the fastest growing segments of the U.S. healthcare market. With our existing capacity and the capability to reach 97% of the U.S. population, we are well positioned to scale and continue delivering essential medications to patients with no friction, no delays, and no barriers.\"2026 First Quarter Financial Results Selected Financial Information(Thousands of U.S. dollars,except per share amounts and percentages)For the three-month periods ended March 31,For the three-month period ended December 31, 202620252025Revenue$19,394$6,931$14,314Gross Profit10,7083,4927,852Gross Profit Margin55%50%55%Net Income (Loss) from Operations(4,676)(38)(3,057)Adjusted EBITDA1(2,264)218(2,075)Cash Prov...